In many cases the cause is unknown. Surgery that implants a device into the eye to provide a slow and sustained release of a medication. Louis University School of Megicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. She is a fellow of the American Academy of Ophthalmology. Yonsei Med J. 2005;465:585-96. The ophthalmologist will check for this, and advise you if it occurs. Using a slit lamp, an ophthalmologist can detect white blood cells accumulating in different parts of the eye. Am J Ophthalmol. Sometimes uveitis is caused by bacteria or a virus in the eye. B J Ophthalmol. 2007;9112:1680-5. shied received a Bachelor of Science degree with donors from the University of Notre Dame.
The EGP-437 combination product, EyeGates first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGates proprietary innovative drug delivery system, the EyeGate II Delivery System. In addition, EyeGate is developing, through its wholly-owned Jade subsidiary, products using cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S), a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. EyeGate intends to initiate a clinical study for Jades lead product candidate for corneal epithelial defects by year-end 2016. no dataFor more information, please visit www.EyeGatePharma.com . Safe Harbor Statement: Some of the statements in this press release are forward-looking and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGates products, including EyeGates EGP-437 combination product and those of Jade, a wholly owned subsidiary of EyeGate, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading Risk Factors contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2016, and our Quarterly Report on Form 10-Q, as filed with the SEC on November 1, 2016 or described in our other public filings. no dataOur results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/eyegate-pharmaceuticals-reports-third-quarter-132000500.html